Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4212) 4212
Publication (391) 391
Book / eBook (247) 247
Book Review (40) 40
Book Chapter (18) 18
Dissertation (6) 6
Conference Proceeding (2) 2
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2801) 2801
male (2157) 2157
animals (1892) 1892
index medicus (1783) 1783
female (1456) 1456
respiratory system (1137) 1137
lung diseases, interstitial - chemically induced (1069) 1069
lung - pathology (1001) 1001
middle aged (985) 985
mice (968) 968
aged (860) 860
pulmonary fibrosis - chemically induced (771) 771
lung - drug effects (686) 686
lungs (668) 668
adult (643) 643
lung diseases - chemically induced (633) 633
rats (615) 615
lung diseases (593) 593
disease models, animal (548) 548
inflammation (508) 508
lung - metabolism (476) 476
pulmonary fibrosis (447) 447
pulmonary fibrosis - pathology (446) 446
research (426) 426
bleomycin (415) 415
mice, inbred c57bl (413) 413
lung (407) 407
oncology (399) 399
toxicology (394) 394
fibrosis (388) 388
respiratory tract diseases (385) 385
risk factors (365) 365
tomography, x-ray computed (358) 358
antineoplastic agents - adverse effects (344) 344
rodents (332) 332
cancer (317) 317
health aspects (308) 308
expression (304) 304
physiology (298) 298
pneumonia - chemically induced (294) 294
toxicity (293) 293
medicine (292) 292
disease (285) 285
time factors (282) 282
therapy (275) 275
cell biology (274) 274
lung neoplasms - drug therapy (271) 271
pharmacology & pharmacy (263) 263
research article (261) 261
pneumonia (258) 258
pulmonary fibrosis - metabolism (255) 255
medicine, general & internal (248) 248
care and treatment (244) 244
oxidative stress (240) 240
lung diseases - pathology (238) 238
interstitial lung disease (237) 237
immunology (230) 230
lung diseases, interstitial - diagnosis (225) 225
biochemistry & molecular biology (218) 218
rats, sprague-dawley (217) 217
treatment outcome (217) 217
bronchoalveolar lavage fluid - cytology (212) 212
diseases (212) 212
proteins (211) 211
pathology (209) 209
chemotherapy (208) 208
aged, 80 and over (202) 202
acute lung injury (201) 201
diagnosis (200) 200
lung diseases, interstitial - diagnostic imaging (196) 196
cells (195) 195
pathogenesis (194) 194
bronchoalveolar lavage fluid - chemistry (193) 193
cytokines (193) 193
lung injury (193) 193
analysis (190) 190
lung diseases, interstitial - pathology (190) 190
apoptosis (189) 189
radiography (188) 188
macrophages (184) 184
collagen (181) 181
dose-response relationship, drug (178) 178
acute lung injury - chemically induced (177) 177
gene expression (174) 174
bronchoalveolar lavage (172) 172
lung cancer (171) 171
multidisciplinary sciences (171) 171
diagnosis, differential (170) 170
physiological aspects (170) 170
carcinoma, non-small-cell lung - drug therapy (169) 169
article (166) 166
bleomycin - toxicity (166) 166
respiratory-distress-syndrome (166) 166
lung diseases, interstitial - drug therapy (165) 165
activation (164) 164
fibroblasts (164) 164
mortality (164) 164
exposure (163) 163
lung - diagnostic imaging (163) 163
mice, knockout (163) 163
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (209) 209
West Park Healthcare Centre - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (6) 6
Scarborough Hospital - General (5) 5
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Toronto East General Hospital - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Markham Stouffville Hospital - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Missing (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Lakeridge Health Sciences - Online (1) 1
Mt Sinai Hospital - Pathology (1) 1
Online Resources - Online (1) 1
Providence Healthcare - Stacks (1) 1
Royal Ontario Museum - Periodical Stacks (1) 1
Trillium Health Centre - Stacks (1) 1
UofT Schools - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Hospital Department (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4093) 4093
Japanese (172) 172
French (82) 82
German (42) 42
Spanish (29) 29
Chinese (19) 19
Italian (11) 11
Portuguese (9) 9
Dutch (8) 8
Polish (8) 8
Korean (3) 3
Romanian (3) 3
Russian (2) 2
Swedish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Danish (1) 1
Hungarian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Statin-Associated Side Effects
by Thompson, Paul D., MD and Panza, Gregory, MS and Zaleski, Amanda, MS and Taylor, Beth, PhD
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 20, pp. 2395 - 2410
Abstract Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well tolerated, but associated with various statin-associated... 
Cardiovascular | Internal Medicine | rhabdomyolysis | skeletal muscle | interstitial lung disease | myopathy | C-REACTIVE PROTEIN | RANDOMIZED CONTROLLED-TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | FORCE 2014 UPDATE | PRIMARY-PREVENTION TRIAL | INDUCED MUSCLE TOXICITY | INTERSTITIAL LUNG-DISEASE | CENTRAL-NERVOUS-SYSTEM | OF-THE-LITERATURE | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | Liver Function Tests | Sleep Wake Disorders - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - immunology | Myalgia - chemically induced | Humans | Hyperlipidemias - drug therapy | Risk Factors | Lung Diseases, Interstitial - chemically induced | Tendon Injuries - chemically induced | Necrosis - chemically induced | Brain - drug effects | Rupture - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Stroke - chemically induced | Cognition Disorders - etiology | Depression - chemically induced | Rhabdomyolysis - chemically induced | Antibodies - blood | Diabetes Mellitus - chemically induced | Acute Kidney Injury - chemically induced | Muscular Diseases - chemically induced | Testosterone - blood | Autoimmune Diseases - chemically induced | Hyperlipidemias - complications | Viral antibodies | Complications and side effects | Enzymes | Thiols | Antibodies | Diabetes | Cardiology | Statins | Cardiovascular agents | Creatine kinase | Muscles | Creatine | Respiratory tract diseases | Studies | Musculoskeletal system | Genotype & phenotype | Mortality | Clinical trials | Lipids | Clinical medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Understanding, recognizing, and managing toxicities of targeted anticancer therapies
by Dy, Grace K and Adjei, Alex A
CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 07/2013, Volume 63, Issue 4, pp. 249 - 279
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for... 
toxicity | kinase inhibitors | therapeutic index | targeted agents | mechanism‐based toxicity | immunotherapeutic agents | off‐target toxicity | mechanism-based toxicity | off-target toxicity | MEK INHIBITOR TRAMETINIB | PULMONARY ARTERIAL-HYPERTENSION | I DOSE-ESCALATION | CHRONIC MYELOID-LEUKEMIA | GROWTH-FACTOR RECEPTOR | ONCOLOGY | PLACEBO-CONTROLLED TRIAL | III CLINICAL-TRIAL | SQUAMOUS-CELL CARCINOMAS | TIVANTINIB ARQ 197 | SIGNAL-REGULATED KINASE | Mood Disorders - chemically induced | Drug Eruptions - etiology | Peripheral Nervous System Diseases - chemically induced | Bone Marrow Diseases - chemically induced | Cachexia - chemically induced | Endocrine System Diseases - chemically induced | Pleural Effusion - chemically induced | Humans | Drug Eruptions - therapy | Immune System Diseases - chemically induced | Lung Diseases, Interstitial - chemically induced | Thrombocytopenia - chemically induced | Diarrhea - chemically induced | Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Hyperbilirubinemia - chemically induced | Venous Thromboembolism - chemically induced | Vision Disorders - chemically induced | Hemorrhage - chemically induced | Heart Diseases - chemically induced | Hyperlipidemias - chemically induced | Magnesium - blood | Antimitotic agents | Drugs | Prevention | Complications and side effects | Drug targeting | Antineoplastic agents | Health aspects | Risk factors | Proteins | Side effects | Genomics | Cytotoxicity | Molecular biology | Cancer therapies | Cells | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Biologics-induced autoimmune diseases
by Perez-Alvarez, Roberto and Pérez-De-Lis, Marta and Ramos-Casals, Manuel and BIOGEAS Study Grp and BIOGEAS study group
Current Opinion in Rheumatology, ISSN 1040-8711, 01/2013, Volume 25, Issue 1, pp. 56 - 64
Purpose of review Biological agents are therapies designed to target a specific molecular component of the immune system, and are currently licensed for use in... 
induced autoimmune disease | Adalimumab | etanercept | infliximab | rituximab | RHEUMATOID-ARTHRITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | HEMOPHAGOCYTIC SYNDROME | RITUXIMAB THERAPY | ULCERATIVE-COLITIS | RHEUMATOLOGY | adalimumab | NEW-ONSET PSORIASIS | FACTOR-ALPHA THERAPY | INFLAMMATORY-BOWEL-DISEASE | HENOCH-SCHONLEIN PURPURA | MACROPHAGE ACTIVATION SYNDROME | Eye Diseases - chemically induced | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Humans | Inflammatory Bowel Diseases - chemically induced | Immunologic Factors - adverse effects | Lung Diseases, Interstitial - chemically induced | Autoimmune Diseases - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Interstitial Lung Disease in Japanese Patients with Lung Cancer: A Cohort and Nested Case-Control Study
by Kudoh, Shoji and Kato, Harubumi and Nishiwaki, Yutaka and Fukuoka, Masahiro and Nakata, Kouichiro and Ichinose, Yukito and Tsuboi, Masahiro and Yokota, Soichiro and Nakagawa, Kazuhiko and Suga, Moritaka and Japan Thoracic Radiology Group and Jiang, Haiyi and Itoh, Yohji and Armour, Alison and Watkins, Claire and Higenbottam, Tim and Nyberg, Fredrik and Japan Thoracic Radiology Grp and Japan Thoracic Radiology Group
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 06/2008, Volume 177, Issue 12, pp. 1348 - 1357
Rationale: Interstitial lung disease (ILD) occurs in Japanese patients with non-small cell lung cancer (NSCLC) receiving gefitinib. Objectives: To elucidate... 
Chemotherapy | Japanese patients | Gefitinib | Interstitial lung disease | Non-small cell lung cancer | non-small cell lung cancer | RISK-FACTORS | PHASE-III | ASIAN ORIGIN | gefitinib | PNEUMONIA | chemotherapy | IRESSA | interstitial lung disease | RESPIRATORY SYSTEM | GROWTH-FACTOR | INHIBITORS | PULMONARY-FIBROSIS | PREDICTIVE FACTORS | CRITICAL CARE MEDICINE | Japan - epidemiology | Lung Neoplasms - drug therapy | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Logistic Models | Male | Lung Diseases, Interstitial - chemically induced | Protein Kinase Inhibitors - adverse effects | Case-Control Studies | Incidence | Lung Diseases, Interstitial - mortality | Quinazolines - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung Diseases, Interstitial - epidemiology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Imatinib-induced irreversible interstitial lung disease: A case report
by Zhang, Ping and Huang, Jingfeng and Jin, Fangfang and Pan, Jiaohai and Ouyang, Guifang
Medicine, ISSN 0025-7974, 02/2019, Volume 98, Issue 8, p. e14402
Rationale: Imatinib mesylate (imatinib) is a classic tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Although it is well tolerated by most... 
MESYLATE | MEDICINE, GENERAL & INTERNAL | chronic myeloid leukemia | interstitial pneumonia fibrosis | imatinib mesylate | nilotinib | Glucocorticoids - therapeutic use | Lung - pathology | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Tomography, X-Ray Computed | Lung Diseases, Interstitial - chemically induced | Protein Kinase Inhibitors - adverse effects | Lung Diseases, Interstitial - drug therapy | Imatinib Mesylate - therapeutic use | Lung Diseases, Interstitial - diagnosis | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Imatinib Mesylate - adverse effects | Prednisone - therapeutic use | Case studies | Development and progression | Lung diseases, Interstitial | Care and treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review
by Roubille, Camille, MD and Haraoui, Boulos, MD, FRCPC
Seminars in Arthritis and Rheumatism, ISSN 0049-0172, 2014, Volume 43, Issue 5, pp. 613 - 626
Abstract Objective To review published cases of induced or exacerbated interstitial lung disease (ILD) in rheumatoid arthritis (RA) associated with... 
Rheumatology | Pneumonitis | Pulmonary fibrosis | Tocilizumab | Rheumatoid arthritis | Rituximab | TNF inhibitors | Leflunomide | Interstitial lung disease | Methotrexate | LOW-DOSE METHOTREXATE | POSTMARKETING SURVEILLANCE | RISK-FACTORS | PULMONARY-FUNCTION | RHEUMATOLOGY | INFLIXIMAB THERAPY | FIBROSING ALVEOLITIS | INDUCED ACUTE PNEUMONITIS | DOUBLE-BLIND | ORGANIZING PNEUMONIA | JAPANESE PATIENTS | Biological Factors - therapeutic use | Arthritis, Rheumatoid - drug therapy | Humans | Antirheumatic Agents - adverse effects | Lung Diseases, Interstitial - chemically induced | Biological Factors - adverse effects | Antirheumatic Agents - therapeutic use | Rheumatoid factor | Antirheumatic agents | Osteoarthritis | Lung diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases
by Ramos-Casals, Manuel and Brito-Zerón, Pilar and Muñoz, Sandra and Soria, Natalia and Galiana, Diana and Bertolaccini, Laura and Cuadrado, Maria-Jose and Khamashta, Munther A
Medicine, ISSN 0025-7974, 07/2007, Volume 86, Issue 4, pp. 242 - 251
Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. With this use and... 
CUTANEOUS VASCULITIS | MEDICINE, GENERAL & INTERNAL | SYSTEMIC-LUPUS-ERYTHEMATOSUS | CROHNS-DISEASE | ETANERCEPT THERAPY | DRUG-INDUCED LUPUS | HENOCH-SCHONLEIN PURPURA | INFLIXIMAB-INDUCED LUPUS | NECROSIS-FACTOR-ALPHA | LEUKOCYTOCLASTIC VASCULITIS | RHEUMATOID-ARTHRITIS PATIENTS | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Myositis - chemically induced | Lung Diseases, Interstitial - chemically induced | Antibodies, Monoclonal, Humanized | Anti-Inflammatory Agents - adverse effects | Etanercept | Infliximab | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Registries | Vasculitis - chemically induced | Adverse Drug Reaction Reporting Systems | Receptors, Tumor Necrosis Factor - administration & dosage | Antiphospholipid Syndrome - chemically induced | Immunoglobulin G - administration & dosage | Immunoglobulin G - adverse effects | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Adolescent | Arthritis - drug therapy | Aged | Lupus Erythematosus, Systemic - chemically induced | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drugs | Usage | Anti-inflammatory drugs | Development and progression | Dosage and administration | Autoimmune diseases | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights